Inhibrx Biosciences, Inc.
INBX
Positions held
Your positionsINBX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Inhibrx Biosciences operates in the biotechnology sector, which is characterized by rapid innovation and potential for high returns as new therapies are developed.
- The company has a market capitalization of approximately $1.37 billion, indicating a significant presence in the biotech industry.
- Despite recent challenges, Inhibrx's target mean price is $266.67, suggesting potential upside from current levels.
- Inhibrx has a negative profit margin and operating margin, reflecting ongoing financial struggles and lack of revenue generation.
- The company reported a net income loss of $36.65 million in Q2 2026, continuing a trend of negative earnings over several quarters.
- The stock has a 'Strong Sell' signal with a score of -16.00, indicating bearish sentiment among analysts.
Fundamentals
| Market cap | $1.37B | Enterprise value | $1.41B | Trailing P/E | — | Forward P/E | -10.59 |
| PEG | — | Price / book | -25.75 | Beta | 3.82 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -17.7% | ROA | -43.6% | Debt / equity | — |
| Current ratio | 5.07 | Free cash flow | -$85.10M | Analyst recommendation | none | Mean target | $266.67 |
| 52w high | $155.29 | 52w low | $28.16 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $1.3M |
| Op margin | — | — | — | — | -2106.8% |
| Net income | -$36.6M | -$33.4M | -$32.8M | -$35.3M | -$28.7M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$32.1M | -$30.9M | -$30.9M | -$33.8M | -$27.4M |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $1.3M | $0.2M | $1.8M | $1.3M |
| Op margin | -10386.5% | -165724.0% | -12178.9% | -8864.2% |
| Net income | -$140M | $1.7B | -$241M | -$115M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$135M | -$331M | -$219M | -$115M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-02 · Inhibrx’s Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
2026-09-29 · Inhibrx Biosciences (INBX) Faces A Pipeline Valuation Test Following Its Sharp Rerating
2026-09-28 · Inhibrx Biosciences Insider Bought Shares Worth $998,784, According to a Recent SEC Filing
2026-09-24 · Inhibrx’s Cancer Drug Nearly Doubled Response Rate, So Why Did the Stock Fall?
2026-09-23 · Inhibrx Biosciences Insider Bought Shares Worth $500,000, According to a Recent SEC Filing
2026-09-17 · Inhibrx Biosciences Insider Bought Shares Worth $500,000, According to a Recent SEC Filing
2026-09-16 · Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?
2026-09-08 · Inhibrx Shares Rise After Positive Phase 2 Head and Neck Cancer Data
2026-09-08 · Inhibrx Biosciences Says Cancer Combination Therapy Shows Improved Response in Phase 2 Study
2026-09-08 · Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
2026-09-04 · Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study
2026-08-13 · Inhibrx Reports Second Quarter 2026 Financial Results
Price (daily)
Full chart · RSI · MACD · patterns